ARVINAS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.65 USD | +4.18% |
|
+10.49% | -15.82% |
| May. 16 | Sector Update: Health Care Stocks Steady Premarket Thursday | MT |
| May. 16 | Sector Update: Health Care | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the ESMO Data Presentati...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
34.65
USD
Average target price
68.44
USD
Spread / Average Target
+97.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.82% | 2.28B | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Transcript : Arvinas, Inc. - Special Call